CSI Market
Sign In | Register

Denali Therapeutics Inc (DNLI) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access DNLI quarterly Cash Flow →
Cash flow data covering Denali Therapeutics Inc–Dec 31 2021 offers a view into how Dec 31 2025's cash position has developed alongside business activity.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-512.54
Depreciation & amortization11.18
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation99.63
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Investment Income Net Amortization Of Discount And Premium-
Increase Decrease In Deferred Rent-
Investment Income Amortization Of Discount-10.25
Increase Decrease In Deferred Liability Capitalized Research And Development Costs6.97
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable-7.52
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities0.47
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.54
Other Working Capital0.77
Other Noncash Income (Expense)0.05
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.82
Discontinued operations0.00
Net Cash flow from Operating Activities-412.60
Investing Activities
Capital Expenditures-9.50
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities706.05
Payments to Acquire Marketable Securities-441.26
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities255.28
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-0.32
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock8.46
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net12.71
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents176.54
Capital Expenditures Incurred But Not Yet Paid-
Proceeds From Issuance Of Common Stock In Connection With Collaboration Agreement-
Finance Lease Principal Payments-8.17
Proceeds From Issuance Of Common Stock And Warrants-
Proceeds From Sale Of Revenue Participation Right-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities189.22
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-422.10
Total Cash Flow31.90
4 historic quarters locked

Sign in to unlock the full Denali Therapeutics Inc cash flow history.

Sign In Create Free Account

About Denali Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 26, 2026
  • Source: dnli-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001714899-26-000021

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License